Following the May 2026 and July 2026 NENC Clinical Effectiveness and Governance (CEG) Subcommittee meetings the following NICE TAs and guidelines were referred to the ICB Executive leadership group for approval given their cost impact:
- TA1128: Targeted-release budesonide for treating primary IgA nephropathy
- TA1140: Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over
- TA1142: Dupilumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils
- TA1143: Fezolinetant for treating moderate to severe vasomotor symptoms associated with menopause
- NG28: Type 2 diabetes in adults: management (update)
- TA1148: Sodium zirconium cyclosilicate for treating hyperkalaemia
- TA1152: Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
These have now all been approved by the ICB Executive leadership group and the NENC formulary has been updated accordingly. The May 2026 and July 2026 medicines decisions have been updated to reflect these decisions and can be found at: https://ntag.nhs.uk/meetings/decision-summaries/